 |
| |
| May-11-17 | Downgrade |
Cantor Fitzgerald |
Buy → Neutral |
$21 → $15 |
|
| Mar-17-17 | Reiterated |
Needham |
Buy |
$24 → $22 |
|
| Mar-17-17 | Reiterated |
Maxim Group |
Buy |
$19 → $22 |
|
| Nov-16-16 | Reiterated |
Wedbush |
Outperform |
$56 → $47 |
|
| Nov-10-16 | Reiterated |
Needham |
Buy |
$28 → $24 |
|
| Aug-10-16 | Reiterated |
Maxim Group |
Buy |
$30 → $19 |
|
| Jun-03-16 | Initiated |
Cantor Fitzgerald |
Buy |
$21 |
|
| Mar-02-16 | Reiterated |
Needham |
Buy |
$30 → $28 |
|
| Feb-29-16 | Reiterated |
Wedbush |
Outperform |
$65 → $62 |
|
| Nov-11-15 | Reiterated |
Needham |
Buy |
$32 → $30 |
|
| Aug-18-15 | Reiterated |
WBB Securities |
Strong Buy |
$60 → $75 |
|
| Aug-10-15 | Initiated |
ROTH Capital |
Buy |
$38 |
|
| Mar-18-15 | Reiterated |
Needham |
Buy |
$22 → $32 |
|
| Feb-20-15 | Reiterated |
Maxim Group |
Buy |
$28 → $30 |
|
| Feb-18-15 | Reiterated |
MLV & Co |
Buy |
$19 → $38 |
|
| Nov-13-14 | Reiterated |
Maxim Group |
Buy |
$20 → $28 |
|
| Mar-25-14 | Reiterated |
Needham |
Buy |
$15 → $17 |
|
| Apr-15-13 | Initiated |
MLV & Co |
Buy |
$14 |
|
| Mar-19-13 | Resumed |
Needham |
Buy |
$12 |
|
| Dec-28-12 | Reiterated |
Burrill Institutional Research |
Mkt Outperform |
$19 → $16 |
|
|
|
| Sep-12-17 12:19AM | ETFs with exposure to Omeros Corp. : September 12, 2017 Capital Cube |
| Aug-31-17 07:54PM | ETFs with exposure to Omeros Corp. : August 31, 2017 Capital Cube |
| Aug-25-17 11:04AM | Omeros Corp. :OMER-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017 Capital Cube |
| Aug-23-17 11:00AM | Omeros Responds to Statnews.com Story Business Wire |
| Aug-22-17 09:46AM | Omeros Shares Lower After Completing Stock Offering, Juno Dips - Biotech Movers TheStreet.com |
| 09:02AM | Omeros Corp. breached its 50 day moving average in a Bearish Manner : OMER-US : August 22, 2017 Capital Cube |
| Aug-21-17 03:25PM | Omeros Closes $68.3 Million Public Offering of Common Stock Business Wire -5.58% |
| Aug-15-17 09:34AM | Omeros's stock sinks after share offering prices at a discount MarketWatch -8.49% |
| 09:17AM | Omeros Announces Pricing of Public Offering of Common Stock Business Wire |
| Aug-14-17 04:05PM | Omeros Announces Public Offering of Common Stock Business Wire |
| 12:55PM | Omeros Data Show Continued Improvement in Patients with IgA Nephropathy Treated with OMS721 Business Wire |
| Aug-13-17 11:25AM | Edited Transcript of OMER earnings conference call or presentation 8-Aug-17 8:30pm GMT Thomson Reuters StreetEvents |
| Aug-10-17 08:00AM | Today's Research Reports on Trending Tickers: Omeros Corporation and Zynerba Pharmaceuticals ACCESSWIRE -5.38% |
| 07:00AM | Omeros to Present at the 2017 Wedbush PacGrow Healthcare Conference Business Wire |
| Aug-08-17 05:49PM | Omeros reports 2Q loss Associated Press |
| 04:02PM | Omeros Corporation Reports Second Quarter 2017 Financial Results Business Wire |
| 11:00AM | Investor Network: Omeros Corporation to Host Earnings Call ACCESSWIRE |
| 07:10AM | Corporate News Blog - FDA Grants Orphan Drug Designation to Omeros OMS721 for Treatment of IgA Nephropathy ACCESSWIRE |
| Aug-04-17 11:10AM | FDA Grants Orphan Drug Designation to Omeros OMS721 for Treatment of IgA Nephropathy Business Wire +6.93% |
| Aug-02-17 07:00AM | Omeros Corporation to Announce Second Quarter 2017 Financial Results on August 8, 2017 Business Wire |
| Jul-25-17 06:30AM | 3 Stocks That Could Put Nvidia's Returns to Shame Motley Fool |
| Jul-17-17 08:50AM | Today's Research Reports on Stocks to Watch: Sorrento Therapeutics and Omeros Corporation Accesswire |
| Jul-12-17 11:01AM | Technical trading: These four stocks are breaking out of their pattern MarketWatch |
| Jul-06-17 05:45PM | Omeros threatens to sue anonymous detractor American City Business Journals |
| Jul-03-17 09:24AM | Biotech Movers: BioCryst, Omeros, Radius Health TheStreet.com |
| Jun-29-17 08:41AM | Omeros to pursue legal action against short seller for report that shaved 21% off stock this week MarketWatch |
| 08:39AM | Omeros Corporation (OMER) Accuses Short Seller of Manipulation SmarterAnalyst |
| 07:00AM | Omeros Releases Statement in Response to Recent False Report Business Wire |
| Jun-28-17 04:02PM | Here's Why Omeros Corporation Fell as Much as 14.8% Today Motley Fool -9.48% |
| Jun-27-17 04:27PM | These 3 Biotech Stocks Have Doubled This Year; Can They Keep Climbing? Motley Fool -9.36% |
| Jun-19-17 08:00AM | Today's Research Reports on Stocks to Watch: ReWalk Robotics and Omeros Corporation Accesswire |
| Jun-17-17 07:32AM | 3 Stocks Wall Street Hasn't Noticed Motley Fool |
| Jun-16-17 10:53AM | Omeros (OMER) Hits New 52-Week High on Positive FDA Decision Zacks +7.22% |
| Jun-15-17 04:05PM | These 3 Stocks Could Have Doubled Your Money This Year Motley Fool |
| 08:48AM | Harry Boxer: 4 stocks with strong technical momentum MarketWatch |
| Jun-14-17 02:09PM | 2 Longs And 2 Shorts To Watch Benzinga +12.21% |
| 10:27AM | Omeros (OMER) Lead Candidate Gets Breakthrough Designation Zacks |
| Jun-13-17 04:29PM | Why Tesla, Omeros, and Hertz Global Holdings Jumped Today Motley Fool +14.50% |
| 04:06PM | Omeros Corporations Breakthrough Becomes a Clear Danger to Alexion: WBB SmarterAnalyst |
| 04:05PM | Here's Why Omeros Corporation Stock Rose as Much as 16.7% Today Motley Fool |
| 12:48PM | ETFs with exposure to Omeros Corp. : June 13, 2017 Capital Cube |
| 11:30AM | FDA Grants Breakthrough Therapy Designation to Omeros MASP-2 Inhibitor OMS721 for the Treatment of IgA Nephropathy Business Wire |
| 08:30AM | Omeros (OMER) Worth a Look: Stock Adds 11.8% in Session Zacks |
| 08:26AM | Omeros Corp. breached its 50 day moving average in a Bullish Manner : OMER-US : June 13, 2017 Capital Cube |
| 08:00AM | Today's Research Reports on Stocks to Watch: Coherus Biosciences and Omeros Corporation Accesswire |
| Jun-07-17 09:42AM | Omeros: Can the Growth Story Continue? Motley Fool |
| 08:45AM | 5 Top Stocks for June Motley Fool |
| Jun-05-17 04:29PM | 3 Stocks With Exelixis-Like Return Potential Motley Fool |
| Jun-01-17 02:01PM | ETFs with exposure to Omeros Corp. : June 1, 2017 Capital Cube |
| 07:00AM | Omeros Announces OMS721 Presentation at 54th ERA-EDTA Congress Business Wire |
| May-22-17 01:58PM | ETFs with exposure to Omeros Corp. : May 22, 2017 Capital Cube |
| May-19-17 10:23AM | Omeros Corp. :OMER-US: Earnings Analysis: Q1, 2017 By the Numbers : May 19, 2017 Capital Cube |
| May-18-17 08:15AM | Blog Coverage: Omeros' Stock Jumped on Completion of IgA nephropathy Cohort and Additional Positive Results Accesswire |
| May-17-17 12:03PM | Here's Why Omeros Corporation Is Surging Again Today Motley Fool +8.70% |
| 07:00AM | Omeros Announces Completion of IgA Nephropathy Cohort in OMS721 Phase 2 Clinical Trial Business Wire |
| May-16-17 07:16PM | Edited Transcript of OMER earnings conference call or presentation 10-May-17 8:30pm GMT Thomson Reuters StreetEvents |
| May-15-17 04:31PM | 3 Biotech Stocks I'd Buy Right Now Motley Fool |
| May-11-17 12:28PM | Here's Why Omeros Corporation Stock Is Falling Today Motley Fool -8.30% |
| May-10-17 04:36PM | Omeros reports 1Q loss Associated Press |
| 04:02PM | Omeros Corporation Reports First Quarter 2017 Financial Results Business Wire |
| 10:15AM | Investor Network: Omeros Corporation to Host Earnings Call Accesswire |
| May-03-17 04:02PM | Omeros Corporation to Announce First Quarter 2017 Financial Results on May 10, 2017 Business Wire |
| Apr-17-17 09:28AM | Biotech Movers: OncoMed, Incyte, Omeros TheStreet.com |
| Apr-15-17 12:02PM | 3 Biotech Stocks to Buy on Sale Motley Fool |
| Apr-03-17 07:00AM | Omeros to Present at the Needham Healthcare Conference Business Wire |
| Mar-30-17 09:54AM | Biotech Premarket Movers: Halozyme, Omeros, Aralez TheStreet.com +7.50% |
| 09:54AM | Biotech Premarket Movers: Halozyme, Omeros, Aralez |
| 07:00AM | Omeros Reports More Positive Data in OMS721 Phase 2 Trial in Renal Diseases Business Wire |
| Mar-29-17 08:34PM | ETFs with exposure to Omeros Corp. : March 30, 2017 Capital Cube |
| 08:34PM | ETFs with exposure to Omeros Corp. : March 30, 2017 |
| 04:21PM | Top Biotech Stocks for Growth Investors Motley Fool |
| 04:21PM | Top Biotech Stocks for Growth Investors at Motley Fool |
| 09:30AM | Osiris Therapeutics Sees Stock Bounce Up On Restatement, Omeros Readies for Presentations of its OMR-721 Candidate Drug Accesswire |
| Mar-28-17 05:03PM | Here's Why Omeros Corporation Stock Climbed Higher Today Motley Fool +11.29% |
| 05:03PM | Here's Why Omeros Corporation Stock Climbed Higher Today at Motley Fool |
| 12:24PM | 3 Stocks That Could Make You Rich Motley Fool |
| 12:24PM | 3 Stocks That Could Make You Rich at Motley Fool |
| 07:00AM | Omeros Announces OMS721 Presentation at Annual Meeting of the European Society for Blood and Marrow Transplantation Business Wire |
| Mar-27-17 07:00AM | Omeros to Present Results from Dose-Ranging Stage of OMS721 Clinical Trial in Atypical Hemolytic Uremic Syndrome at World Congress of Nephrology Business Wire +9.60% |
| Mar-24-17 09:02AM | Omeros: Power in the Pipeline at Motley Fool |
| Mar-23-17 01:04PM | OMEROS CORP Financials |
| Mar-21-17 09:30AM | Omeros and Keryx are Potential Beneficiaries of New Administration Deregulation Accesswire -5.36% |
| 09:29AM | Omeros Corp. :OMER-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017 |
| 08:22AM | 3 Beaten-Up Biotech Stocks: Are They Bargains? at Motley Fool |
| Mar-20-17 08:19AM | Omeros Corp. breached its 50 day moving average in a Bearish Manner : OMER-US : March 20, 2017 +11.48% |
| Mar-17-17 04:11PM | Edited Transcript of OMER earnings conference call or presentation 16-Mar-17 8:30pm GMT -9.14% |
| Mar-16-17 04:34PM | Omeros reports 4Q loss |
| 04:30PM | Omeros Corp Earnings Call scheduled for 4:30 pm ET today |
| 04:07PM | OMEROS CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits |
| 04:05PM | Omeros Corporation Reports Fourth Quarter and Year-End 2016 Financial Results Business Wire |
| 07:07AM | Q4 2016 Omeros Corp Earnings Release - After Market Close |
| Mar-14-17 02:05PM | 5 Earnings Short-Squeeze Plays: Tiffany, Athene and More |
| Mar-10-17 07:00AM | Omeros Corporation to Announce Fourth Quarter and Year-End 2016 Financial Results on March 16, 2017 Business Wire |
| Mar-02-17 07:00AM | Omeros to Present at the Cowen and Company Annual Health Care Conference Business Wire |
| Mar-01-17 07:00AM | Omeros Reports Additional Positive Results from OMS721 Phase 2 Trial in Patients with Stem Cell Transplant-Associated Thrombotic Microangiopathy Business Wire |
| Feb-26-17 03:09PM | 3 Stocks That Could Make You Rich at Motley Fool |
| Feb-08-17 07:25AM | Omeros Corp. breached its 50 day moving average in a Bullish Manner : OMER-US : February 8, 2017 |
| Jan-19-17 01:40PM | ETFs with exposure to Omeros Corp. : January 19, 2017 |
| Jan-03-17 02:37PM | ETFs with exposure to Omeros Corp. : January 3, 2017 |
| Dec-23-16 09:35AM | Omeros Corp. Value Analysis (NASDAQ:OMER) : December 23, 2016 +7.22% |
|
|
|
|
| Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use during cataract surgery or intraocular lens replacement. Its clinical programs include OMS721 that is in Phase III clinical trial for the treatment of atypical hemolytic uremic syndrome; and in Phase II clinical trial to treat thrombotic microangiopathies, IgA nephropathy, and other renal diseases. The company's clinical programs also consists of OMS824, which is in Phase II clinical trial for the treatment of Huntington's diseases and schizophrenia; OMS405 that is in Phase II clinical trial to treat opioid and nicotine addiction; and OMS201, which is in Phase I/II clinical trial for use during urological procedures. Its preclinical programs comprise OMS527 for the treatment of addiction and compulsive disorders, as well as for movement disorders; OMS906 to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; OMS721 for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; and OMS616 to control surgical and traumatic bleeding. The company's preclinical programs also include GPR17 for the treatment of myelin formation; GPR101 for appetite and eating disorders; GPR151 to treat schizophrenia and cognition; GPR161 for triple-negative breast cancer treatment; GPR183 for the treatment of osteoporosis, and Epstein-Barr virus infections and related diseases; GPR174 for modulation of the immune system; and Antibody Platform for metabolic, CV, oncologic, musculoskeletal, and other disorders. In addition, the company is developing OMS103 that has completed Phase III clinical trial for arthroscopic anterior cruciate ligament reconstruction and arthroscopic partial meniscectomy. Omeros Corporation was incorporated in 1994 and is based in Seattle, Washington. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Kelbon Marcia S. | VP Patent and General Counsel | Aug 21 | Option Exercise | 6.05 | 8,000 | 48,400 | 176,641 | Aug 21 03:21 PM | | JACOBSEN MICHAEL A | VP Finance and CAO | Jun 16 | Option Exercise | 9.37 | 14,000 | 131,180 | 19,500 | Jun 16 08:01 PM | | JACOBSEN MICHAEL A | VP Finance and CAO | Jun 16 | Sale | 24.95 | 12,000 | 299,400 | 7,500 | Jun 16 08:01 PM | | JACOBSEN MICHAEL A | VP Finance and CAO | Jun 15 | Option Exercise | 9.37 | 14,000 | 131,180 | 17,500 | Jun 15 07:02 PM | | JACOBSEN MICHAEL A | VP Finance and CAO | Jun 15 | Sale | 22.45 | 12,000 | 269,400 | 5,500 | Jun 15 07:02 PM | | JACOBSEN MICHAEL A | VP Finance and CAO | Jun 14 | Option Exercise | 9.37 | 12,850 | 120,405 | 12,850 | Jun 15 07:02 PM | | JACOBSEN MICHAEL A | VP Finance and CAO | Jun 14 | Sale | 19.95 | 9,350 | 186,533 | 3,500 | Jun 15 07:02 PM | | JACOBSEN MICHAEL A | VP Finance and CAO | Jun 13 | Option Exercise | 9.37 | 2,650 | 24,831 | 2,650 | Jun 15 07:02 PM | | JACOBSEN MICHAEL A | VP Finance and CAO | Jun 13 | Sale | 19.95 | 2,650 | 52,868 | 0 | Jun 15 07:02 PM | | Cable Thomas J. | Director | Apr 12 | Sale | 16.49 | 3,000 | 49,474 | 40,067 | Apr 14 02:04 PM | | Kelbon Marcia S. | VP Patent and General Counsel | Mar 20 | Option Exercise | 6.05 | 2,040 | 12,342 | 168,641 | Mar 22 04:06 PM | | Cable Thomas J. | Director | Dec 14 | Sale | 10.21 | 3,000 | 30,642 | 43,067 | Dec 16 09:00 PM | | Demopulos Gregory A MD | Chairman, CEO & President | Dec 07 | Option Exercise | 0.98 | 102,044 | 100,003 | 1,987,029 | Dec 07 09:00 PM | | Demopulos Gregory A MD | Chairman, CEO & President | Dec 07 | Sale | 10.48 | 102,044 | 1,069,033 | 1,884,985 | Dec 07 09:00 PM | | Demopulos Gregory A MD | Chairman, CEO & President | Dec 06 | Option Exercise | 0.98 | 102,040 | 99,999 | 1,987,025 | Dec 07 09:00 PM | | Demopulos Gregory A MD | Chairman, CEO & President | Dec 06 | Sale | 10.80 | 102,040 | 1,101,808 | 1,884,985 | Dec 07 09:00 PM | | Demopulos Gregory A MD | Chairman, CEO & President | Dec 05 | Option Exercise | 0.98 | 102,040 | 99,999 | 1,987,025 | Dec 07 09:00 PM | | Demopulos Gregory A MD | Chairman, CEO & President | Dec 05 | Sale | 10.71 | 102,040 | 1,092,644 | 1,884,985 | Dec 07 09:00 PM | | Demopulos Gregory A MD | Chairman, CEO & President | Dec 02 | Option Exercise | 0.98 | 283,203 | 277,539 | 1,884,985 | Dec 02 09:40 PM | | Demopulos Gregory A MD | Chairman, CEO & President | Dec 02 | Sale | 11.00 | 102,040 | 1,122,593 | 1,703,822 | Dec 02 09:40 PM | | Demopulos Gregory A MD | Chairman, CEO & President | Dec 01 | Option Exercise | 0.98 | 106,521 | 104,391 | 1,810,343 | Dec 02 09:40 PM | | Demopulos Gregory A MD | Chairman, CEO & President | Dec 01 | Sale | 11.57 | 106,521 | 1,232,063 | 1,703,822 | Dec 02 09:40 PM | | Demopulos Gregory A MD | Chairman, CEO & President | Nov 30 | Option Exercise | 0.98 | 97,559 | 95,608 | 1,801,381 | Dec 02 09:40 PM | | Demopulos Gregory A MD | Chairman, CEO & President | Nov 30 | Sale | 12.21 | 97,559 | 1,191,478 | 1,703,822 | Dec 02 09:40 PM | | Kelbon Marcia S. | VP Patent and General Counsel | Oct 12 | Option Exercise | 6.05 | 3,004 | 18,174 | 166,601 | Oct 12 09:00 PM |
|
|
|
|
|
|
